Matinas BioPharma Holdings, Inc. Annual report pursuant to Section 13 and 15(d)

Income Taxes (Details Narrative) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details Narrative) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Tax Credit Carryforward [Line Items]
Deferred tax assets, valuation allowance	$ 25,206	$ 19,702
Valuation allowance, deferred tax asset, increase (decrease), amount	5,500
Operating loss carryforwards	$ 38,100
Operating loss carryforwards, expiration year	2032
Operating loss carryforwards with no expiration	$ 45,000
Sale of net operating losses	$ 1,100	$ 1,000
Limitations on Net operating loss deductibility, description	In addition, the Tax Cuts and Jobs Act, signed into law on December 22, 2017 imposes significant additional limitations on the deductibility of interest and limits net operating loss (NOL) deductions to 80% of net taxable income for losses arising in taxable years beginning after December 31, 2017.
Federal and State Research and Development Tax Credit Carryforwards [Member]
Tax Credit Carryforward [Line Items]
Operating loss carryforwards	$ 2,300